Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan

Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan

<p>Optimal management of multiple myeloma (MM) remains challenging, particularly among patients with transplant-ineligible newly diagnosed MM (TIE NDMM). Daratumumab + lenalidomide + dexamethasone (DRd) is approved in Japan for the treatment of TIE NDMM. A previously reported real-world, retro...

Descrizione completa

Salvato in:

Dettagli Bibliografici
Autore principale:	Kazuhito Suzuki (22688384) (author)
Altri autori:	Miku Ito (22688387) (author), Chika Sakai (5712761) (author), Hiroaki Tsuchiya (2437369) (author), David Bin-Chia Wu (7251623) (author), Yosuke Koroki (12979839) (author)
Pubblicazione:	2025
Soggetti:	Medicine Pharmacology Biotechnology Immunology Cancer Science Policy Mental Health Daratumumab duration of treatment lenalidomide newly diagnosed multiple myeloma overall survival real-world evidence
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant
di: Saad Z. Usmani (8338341)
Pubblicazione: (2025)

Early daratumumab-based therapy demonstrates significant effectiveness in patients with relapsed and refractory multiple myeloma: a real-world retrospective investigation
di: Yi Chen (38576)
Pubblicazione: (2025)

Table 1_Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.docx
di: Bin Hu (122268)
Pubblicazione: (2025)

Image 2_Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.tif
di: Bin Hu (122268)
Pubblicazione: (2025)

Image 1_Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.tif
di: Bin Hu (122268)
Pubblicazione: (2025)

Image 5_Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.tif
di: Bin Hu (122268)
Pubblicazione: (2025)

Image 4_Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.tif
di: Bin Hu (122268)
Pubblicazione: (2025)

Image 3_Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.tif
di: Bin Hu (122268)
Pubblicazione: (2025)

Image 7_Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.tif
di: Bin Hu (122268)
Pubblicazione: (2025)

Image 6_Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.tif
di: Bin Hu (122268)
Pubblicazione: (2025)

Image 9_Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.tif
di: Bin Hu (122268)
Pubblicazione: (2025)

Image 8_Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.tif
di: Bin Hu (122268)
Pubblicazione: (2025)

Data Sheet 1_Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.docx
di: Bin Hu (122268)
Pubblicazione: (2025)

Supplementary information files for "Different thermal and solubility properties with an identical crystal structure – case of lenalidomide hydrate"
di: Qi Zhang (28502)
Pubblicazione: (2025)

Data Sheet 1_Combination therapy of ofatumumab and daratumumab in patients with severe anti-NMDA receptor encephalitis.docx
di: Baojie Wang (9373937)
Pubblicazione: (2025)

Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression.
di: James G. Lefevre (11303976)
Pubblicazione: (2025)

Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx
di: Øystein Fluge (200378)
Pubblicazione: (2025)

Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff
di: Øystein Fluge (200378)
Pubblicazione: (2025)

Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff
di: Øystein Fluge (200378)
Pubblicazione: (2025)

Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff
di: Øystein Fluge (200378)
Pubblicazione: (2025)

Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff
di: Øystein Fluge (200378)
Pubblicazione: (2025)

Data Sheet 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.pdf
di: Øystein Fluge (200378)
Pubblicazione: (2025)

Data Sheet 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.pdf
di: figshare admin frontiersin (4545187)
Pubblicazione: (2025)

Model parameters with descriptions and default values. The right-hand side column gives the parameter values for a simplified model (Null-N).
di: James G. Lefevre (11303976)
Pubblicazione: (2025)

Optimal control solutions for the linear cost function with zero or default off-target drug effect (), no immune response (), reduced expression switching (, default ), and induced loss of expression set to either zero or the default value ().
di: James G. Lefevre (11303976)
Pubblicazione: (2025)

Selected optimal control solutions for the linear cost function where either expression switching (top row, ) or drug induced loss of expression (bottom row, ) is removed from the model.
di: James G. Lefevre (11303976)
Pubblicazione: (2025)

Optimal control solutions for the linear cost function with increased off-target drug effect (; default 0.1), reduced expression switching (, default ), reduced or default immune strength (, default 0.15), and default or increased drug induced loss of expression (, default 0.2).
di: James G. Lefevre (11303976)
Pubblicazione: (2025)

Optimal control solutions for different off-target drug effect magnitudes (); default value .
di: James G. Lefevre (11303976)
Pubblicazione: (2025)

Optimal control solutions for a range of values of <i>α</i>, which controls the strength of the immune response; default value is .
di: James G. Lefevre (11303976)
Pubblicazione: (2025)

Optimal controls for the full model developed in this paper (Full model) and a simplified version with drug resistance mechanisms and the off-target effect removed (Null-N).
di: James G. Lefevre (11303976)
Pubblicazione: (2025)

Model validation and comparison with Null-N model.
di: James G. Lefevre (11303976)
Pubblicazione: (2025)

Table 1_Case Report: Angioimmunoblastic T-cell lymphoma with coexisting plasma cell tumors: three cases and review of the literature.docx
di: Yulin Yang (839480)
Pubblicazione: (2025)

Image 1_Case Report: Angioimmunoblastic T-cell lymphoma with coexisting plasma cell tumors: three cases and review of the literature.tiff
di: Yulin Yang (839480)
Pubblicazione: (2025)

Image 3_Case Report: Angioimmunoblastic T-cell lymphoma with coexisting plasma cell tumors: three cases and review of the literature.tif
di: Yulin Yang (839480)
Pubblicazione: (2025)

Image 4_Case Report: Angioimmunoblastic T-cell lymphoma with coexisting plasma cell tumors: three cases and review of the literature.tif
di: Yulin Yang (839480)
Pubblicazione: (2025)

Image 2_Case Report: Angioimmunoblastic T-cell lymphoma with coexisting plasma cell tumors: three cases and review of the literature.tif
di: Yulin Yang (839480)
Pubblicazione: (2025)

Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: a retrospective cohort study
di: Yong Zhang (5893)
Pubblicazione: (2025)

T-cell receptor β chain (TCRB) clonality is not significantly associated with disease burden or depth of treatment response. A) Comparison of TCRB clonality (Gini coefficient) between 44 healthy individuals (age > 40 years) and patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM). P-values of significant differences in the univariate analysis (Wilcoxon test) are shown. No significant differences were observed in the multivariate linear model that corrected for age. B) TCRB clonality in MGUS patients at baseline and follow-up (median follow-up 677 days). C) TCRB clonality in MM patients before treatment, stratified by post-treatment depth of response. D) TCRB clonality in SMM patients undergoing carfilzomib, lenalidomide, and dexamethasone (KRd) shown for the entire cohort, and E) stratified by depth of response. F) Line plot comparing the change in individual TCRB clonality among SM
di: David G. Coffey (12486658)
Pubblicazione: (2025)

The apoptosis rate of multiple myeloma cells
di: Long (22802507)
Pubblicazione: (2025)

Impact of early minimal residual disease assessment on the outcomes of patients with systemic light chain amyloidosis
di: Xiaozhe Li (9455068)
Pubblicazione: (2025)